San Francisco, California 94143

  • Related Disorders


To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

Study summary:

The primary objective of this study is to characterize the pharmacokinetics of three ascending doses of lobeline in normal volunteers.


Inclusion Criteria: - Healthy individuals with a body mass index between 18 and 30. - Willing and able to give written consent. - Must have a negative drug test - Females must have a negative pregnancy test prior to study drug administration - Must have no medical contraindications as determined by routine testing Exclusion Criteria: - Please contact the site for more information



Primary Contact:

Principal Investigator
Reese Jones, M.D.
Langley Porter Psychiatric Institute

Backup Contact:


Location Contact:

San Francisco, California 94143
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.